The Procter Gamble Company

Russell James Sheldon

Raymond Todd Henry

William Lee Seibel

Thomas L Cupps

Sophie Eva Bogdan

Jeffrey Joseph Ares

Robert Joseph Isfort

Peter J Maurer

Frank Hallock Ebetino

Adam W Mazur

Daniel P Walker

Feng Wang

Glen E Mieling

Screening methods for identifying compounds that bind to or activate corticotropin releasing factorreceptors (CRFR) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRFRs or of CRFR signal transduction pathways, increase CRFR or increase CRF expression are provided. Pharmaceutical compositions comprising CRFR agonists, antibodies to CRFR and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRFR as the target for intervention and methods for treatment of muscular dystrophies are described.

Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Screening methods for identifying compounds that bind to or activate (Dor Ddopamine receptors individually or in combination) or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of Dor Ddopamine receptors or of Dor Ddopamine receptor signal transduction pathways and increase Dor Ddopamine receptor expression. Pharmaceutical compositions comprising Dor Ddopamine receptor agonists, antibodies to Dor Ddopamine receptors and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using Dor Ddopamine receptors as the target for intervention and methods for treatment of muscular dystrophies are described.

Methods for identifying compounds for regulating muscle mass or function using dopamine receptors

Disclosed are MC-4 and/or MC-3 receptor ligands having the formula:wherein B is a suitable linking group comprising a least one amino acid.

Melanocortin receptor ligands

Screening methods for identifying compounds that regulate skeletal muscle atrophy or hypertrophy, regulate the activity or expression of the vasoactive intestinal peptide receptors (VPAC) or regulate expression of vasoactive intestinal peptide (VIP) or VIP analogs are provided. Methods for the prophylactic or therapeutic treatment of skeletal muscle atrophy utilizing VPAC as the target for intervention are described.

Methods of identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors

Screening methods for identifying compounds that bind to or activate corticotropin releasing factor receptors (CRF R) and regulate or potentially regulate skeletal muscle mass or function in vivo. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF Rs or of CRF R signal transduction pathways, increase CRF R or increase CRF expression are provided. Pharmaceutical compositions comprising CRF R agonists, antibodies to CRF R and methods for increasing skeletal muscle mass or function or for the treatment of skeletal muscle atrophy using CRF R as the target for intervention and methods for treatment of muscular dystrophies are described.

Guanidinylamino heterocycle compounds useful as &agr;-2 adrenoceptor agonists

7-(2-imidazolinylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists

2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agnonists

Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure

Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists

This invention involves compounds having the following structure:

This invention involves compounds having the structure (I) as described in the claims, and enantiomers,optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such noved compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.

This invention involves compounds having the following structure: ##STR1## wherein: a) R.sub.1 is hydrogen; or alkyl; bond (a) is a single or a double bond;

Growing community of inventors

Fairfield, OH, United States of America

Russell James Sheldon